PMID- 18160421
OWN - NLM
STAT- MEDLINE
DCOM- 20080305
LR  - 20161124
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 47
IP  - 2
DP  - 2008 Feb
TI  - Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a 
      reassessment.
PG  - 142-4
AB  - OBJECTIVES: Seronegative spondyloarthropathies, especially ankylosing spondylitis 
      (AS), is shown to be associated with inflammatory bowel disease. 
      Anti-Saccharomyces cerevisiae antibodies (ASCA) is a valid serological marker for 
      Crohn's disease. Presence of ASCA is controversial in AS. In this study, we aimed 
      to investigate the prevalence of ASCA in spondyloarthropathies and its 
      relationship with disease activity and severity. METHODS: One hundred and 
      seventy-five patients with AS, 47 patients with undifferentiated 
      spondyloarthropathy (uSpA) and 103 healthy controls (HCs) were studied. All 
      patients were questioned for demographic features and Bath Ankylosing Spondylitis 
      Disease Activity Index (BASDAI) scores. Radiological damage is assessed by Bath 
      Ankylosing Spondylitis Radiology Index (BASRI) and modified Stroke Ankylosing 
      Spondylitis Spinal Score (mSASSS). ASCA levels were measured with standard ELISA 
      kits. RESULTS: There was an overall increased prevalence of ASCA IgA in AS and 
      uSpA compared with HCs (20.6 and 19.1% vs 5.8%, P = 0.0008 and P = 0.02, 
      respectively). No association was observed between ASCA positivity and 
      erythrocyte sedimentation rate, C-reactive protein levels and BASDAI scores. 
      However, ASCA-positive patients had higher BASRI scores [median BASRI: 7 (2-12) 
      vs 6 (2-12); P = 0.037]. Although not reaching significance, they also had 
      reduced chest expansion and higher Bath Ankylosing Spondylitis Functional Index 
      (BASFI) scores. ASCA-positive AS patients also required anti-tumour necrosis 
      factor therapy more frequently (P = 0.006). CONCLUSIONS: ASCA IgA seems to be 
      more prevalent in AS and uSpA. ASCA can also be a marker of radiological damage 
      and a more severe course in AS.
FAU - Aydin, S Z
AU  - Aydin SZ
AD  - Department of Rheumatology, Marmara University, Faculty of Medicine, Istanbul, 
      Turkey.
FAU - Atagunduz, P
AU  - Atagunduz P
FAU - Temel, M
AU  - Temel M
FAU - Bicakcigil, M
AU  - Bicakcigil M
FAU - Tasan, D
AU  - Tasan D
FAU - Direskeneli, H
AU  - Direskeneli H
LA  - eng
PT  - Journal Article
DEP - 20071226
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antibodies, Fungal)
RN  - 0 (HLA-B27 Antigen)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Antibodies, Fungal/*blood
MH  - Disease Progression
MH  - HLA-B27 Antigen/blood
MH  - Humans
MH  - Immunoglobulin A/*blood
MH  - Immunoglobulin G/blood
MH  - Radiography
MH  - Reference Values
MH  - Saccharomyces cerevisiae/*immunology
MH  - Spondylarthritis/*blood/diagnostic imaging/*immunology
EDAT- 2007/12/28 09:00
MHDA- 2008/03/06 09:00
CRDT- 2007/12/28 09:00
PHST- 2007/12/28 09:00 [pubmed]
PHST- 2008/03/06 09:00 [medline]
PHST- 2007/12/28 09:00 [entrez]
AID - kem324 [pii]
AID - 10.1093/rheumatology/kem324 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2008 Feb;47(2):142-4. doi: 10.1093/rheumatology/kem324. 
      Epub 2007 Dec 26.